Although the precise cause of Parkinson\u2019s disease psychosis is unknown, research shows that the CCK-45C-T variant in the cholecystokinin gene is most frequently linked to the condition. Individuals with Parkinson\u2019s disease psychosis exhibit changes in the brain\u2019s visual processing regions as well as disruptions in the cholinergic brain regions. Dysregulation of the sleep-wake cycle, brainstem dysfunction, poor visual processing, and frontal cognitive dysfunction all play a role in the emergence of Parkinson\u2019s disease psychosis.<\/p>\n\n\n\n
The primary aim of the management of psychosis in Parkinson\u2019s disease is to reduce the frequency and severity of psychotic symptoms with minimal worsening of motor symptoms. Non-pharmacological approaches such as reality orientation, cognitive stimulation therapy (CST), reminiscence therapy, and psychodynamic therapy are preferred as an initial approach before or at least concurrent with medication. So far, the only US FDA-approved medication for psychosis in Parkinson\u2019s disease treatment<\/a> is Acadia\u2019s<\/strong> NUPLAZID<\/strong> (pimavanserin)<\/strong>, an atypical antipsychotic based on the principle of selective 5-HT2A inverse agonist<\/strong> with no dopaminergic, histaminergic, or muscarinic binding. Atypical antipsychotics are often considered initial therapy, reducing the risk of further deterioration in patients. Apart from these, 5-HT3 receptor antagonists<\/strong>, acetylcholinesterase inhibitors<\/strong>, or other antidepressants<\/strong> are also used.<\/p>\n\n\n\n According to the Parkinson\u2019s Disease Foundation, <\/strong>more than 10 million<\/strong> people worldwide are affected by Parkinson\u2019s disease. Of this, 1 million<\/strong> people in the United States suffer from Parkinson\u2019s disease, and roughly 40%<\/strong> suffer from Parkinson\u2019s disease psychosis. Patients with Parkinson\u2019s<\/a> who develop psychosis have a significantly poor quality of life<\/strong> and add significantly to the burden of the disease. Parkinson\u2019s disease psychosis is also linked with nursing home placement and more stress and responsibility for caregivers.<\/p>\n\n\n\n Since some patients are often unaware of their symptoms, while others choose to downplay them and attribute them to an underlying condition or medicine, epidemiological data may also be under-reporting. To accurately establish the worldwide and regional prevalence of psychosis with in-depth patient characteristics and demography analysis, large cohort, population-wide studies are needed.<\/p>\n\n\n\n The most appropriate treatment for psychotic episodes is antipsychotic drugs, and the selection, administration, and dosing of the drugs depend on the situation. Cognitive behavioral therapy is frequently recommended as the first course of treatment, along with drugs for individuals with psychotic symptoms. Family and carer support is essential in managing psychosis as they create a secure therapeutic environment.<\/p>\n\n\n\n Early identification and treatment of Parkinson\u2019s disease psychosis patients are crucial. Managing Parkinson\u2019s disease psychosis\u2019 medication involves Parkinson\u2019s disease psychosis dopaminergic drug optimization and antipsychotic medication selection. Dopaminergic neurons are found in the substantia nigra, a critical brain region that produces the chemical dopamine. Dopamine is necessary for movement and coordination but does not readily cross the blood-brain barrier. Dopaminergic drugs used to treat the motor impairment brought on by Parkinson\u2019s disease may make psychosis worse. Contrarily, commonly prescribed antipsychotic drugs, which inhibit dopamine receptors, can exacerbate motor symptoms in Parkinson\u2019s disease psychosis patients<\/a>.<\/p>\n\n\n\n Prior to 2016, the primary treatment of psychosis in Parkinson\u2019s disease was the atypical antipsychotic drugs,<\/strong> quetiapine, and clozapine. In 2016, the US FDA approved NUPLAZID (pimavanserin), a selective 5-HT2A inverse agonist <\/strong>without dopamine receptor-blocking characteristics. The approval gave ACADIA Pharma<\/strong> a first-mover advantage in the Parkinson\u2019s disease psychosis treatment market. A black box warning<\/strong> about increased mortality in older patients with dementia-related psychosis has been given to the drug as it has been reported that these drugs dramatically increase Parkinsonian motor impairment. No specific research has connected pimavanserin to this risk, and the US FDA sees the risk as a class effect. <\/p>\n\n\n\n Acadia Pharmaceuticals<\/strong> is following key strategies for the commercialization and broader reach of NUPLAZID,<\/strong> with sales specialists focused on promoting the drug to neurologists, psychiatrists, and long-term care physicians. The company is leading numerous clinical programs focused on treating neurological and psychiatric diseases that have been neglected and represent significant unmet medical needs. The company is also immersed in licensing and purchasing additional programs<\/strong> via smart business development, like the recent deal with Stoke.<\/p>\n\n\n\n Comparative clinical trials assessing the effectiveness, side effects, and costs of quetiapine, clozapine, and pimavanserin are essential to the success of NUPLAZID<\/strong>. This knowledge will have a big impact on clinical practice and current Parkinson\u2019s disease psychosis therapy recommendations<\/p>\n\n\n\n As per DelveInsight\u2019s latest \u201cPsychosis in Parkinson\u2019s and Alzheimer\u2019s Disease Market Report<\/strong><\/a>,\u201d NUPLAZID can become a blockbuster<\/strong> drug<\/strong> by 2027, generating a revenue of more than USD 1 billion<\/strong>. The most important reasons will be a first-mover advantage<\/strong>, a monopoly<\/strong>, and additional regulatory approvals.<\/strong><\/p>\n\n\n\n Care for patients with Parkinson\u2019s disease psychosis is more expensive than for those with Parkinson\u2019s disease without psychosis. Patients with Parkinson\u2019s disease psychosis used more resources and had higher all-cause expenses<\/strong>. The expenses associated with long-term care (about 116% higher), nursing homes (about 219% higher), and inpatient care (about 68% higher) showed the largest yearly cost differences between Parkinson\u2019s disease psychosis and Parkinson\u2019s disease without psychosis. <\/p>\n\n\n\n Several drugs are being examined to cater to the unmet needs of patients with Parkinson\u2019s disease psychosis. The late-stage candidates under development include Sunovion Pharmaceuticals<\/strong>\u2019 Ulotaront<\/strong> (SEP-363856)<\/strong> and FANAPT<\/strong> (iloperidone)<\/strong> by Vanda Pharmaceuticals<\/strong>. Among these drugs, as per the analysis by DelveInsight\u2019s analysts, FANAPT <\/strong>has the potential to become a blockbuster for Parkinson\u2019s disease psychosis treatment by generating a revenue of more than a billion<\/strong> after a successful launch in the market. FANAPT is expected to enter the US Parkinson\u2019s disease psychosis treatment market by 2027.<\/p>\n\n\n\n According to DelveInsight\u2019s analysts, the market size of Psychosis in Parkinson\u2019s disease<\/a> was observed to be approximately USD 500 million<\/strong> in the 7MM for 2022. This is expected to increase in the coming years owing to the successful launch of emerging therapies<\/strong>, the rise in the number of cases<\/strong>, and increasing awareness of the disease<\/strong>. Also, significant progress in genomics, neuroimaging, neurobiological<\/strong> and epidemiological frameworks <\/strong>will lead to novel drug discovery and repurposing approaches<\/p>\n\n\n\n Numerous aspects need to be considered when treating Parkinson\u2019s disease psychosis, and each patient should receive personalized care<\/p>\n\n\n\n While standardized diagnostic procedures and international consensus standards for psychosis exist, clinical practice cannot employ the present assessment methods for psychosis as they are too complex. There is a need for innovative<\/strong>, well-tolerated medicines<\/strong> that produce a persistent reduction in symptoms<\/strong>, are efficacious<\/strong> and have improved safety and tolerability profiles<\/strong>. With a continuous focus on genetics and precision medicine, there is hope for new targeted treatments. The present lack of curative therapies and the significant side effects of the existing therapies creates potential for pharmaceutical companies to develop optimal Parkinson\u2019s disease psychosis treatments<\/a> that will delay and prevent disability while keeping psychosis in check.<\/p>\n\n\n\n Parkinson’s disease psychosis is a prevalent occurrence in Parkinson\u2019s disease patients that is associated with significant morbidity and mortality. It is caused by anomalies in dopamine, serotonin, and glutamate neurotransmission induced by Lewy body deposition in the brain.<\/p> <\/div> Epidemiology insights and projection of Parkinson\u2019s disease psychosis <\/strong><\/h2>\n\n\n\n
\n
![\"Parkinson\u2019s](\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/26144721\/Parkinsons-Disease-Psychosis-Epidemiology-Insights-1024x586.png\")
<\/figure>\n\n\n\nMarket insights and projections of Parkinson\u2019s disease psychosis <\/strong><\/h2>\n\n\n\n
![\"Emerging](\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/26150125\/Emerging-Therapies-for-Parkinsons-Disease-Psychosis.png\")
<\/figure>\n\n\n\n\n
FAQs<\/strong><\/h2>\n\n\n\n
![\"Psychosis](\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/05\/26144422\/Psychosis-in-Parkinsons-and-Alzheimers-Disease-Market-Outlook-1024x256.png\")
<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"